US3674850A - Substituted salicylanilides - Google Patents

Substituted salicylanilides Download PDF

Info

Publication number
US3674850A
US3674850A US887427A US3674850DA US3674850A US 3674850 A US3674850 A US 3674850A US 887427 A US887427 A US 887427A US 3674850D A US3674850D A US 3674850DA US 3674850 A US3674850 A US 3674850A
Authority
US
United States
Prior art keywords
salicylanilide
phenoxy
chlorophenoxy
dichloro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US887427A
Inventor
David Richard Duke Osborne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lever Brothers Co
Original Assignee
Lever Brothers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lever Brothers Co filed Critical Lever Brothers Co
Application granted granted Critical
Publication of US3674850A publication Critical patent/US3674850A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups

Definitions

  • the present invention relates to a new class of gerrnicides.
  • halogenated salicylanilides have germicidal properties.
  • the use of such compounds is described in Angew. Chem., 1955, 67, 145 (D. Jerchel and H. Oberheiden) and J. Pharm. Sci., 1961, 50, 831 (H. Lemaire, C.H. Schrarnm and A. Cahn).
  • the invention provides a salicylanilide wherein at least one of the H atoms attached to C in either or'both of the aromatic rings of the salicylanilide residue is replaced by a phenoxy or halogenated phenoxy group of from zero to the total number of the remaining H atoms attached to C in said aromatic rings in replaced by halogen.
  • Another aspect of the invention is a germicidal composition containing a salicylanilide of the invention.
  • the salicylanilides of the invention have been found to be effective in soap against both gram-positive (Staph. aureus) and gram-negative (E. coli) bacteria. Accordingly, another aspect of the invention is a saponaceous composition containing a salicylanilide of the invention.
  • mixtures of the salicylanilides of the invention with certain well known germicides for use in detergent compositions namely, 3,4,4'-trichlorocarbanilide (TCC), 3,5,4'-tribromo-salicylanilide (TBS) and 2,2-dihydroxy-3, 5, 6, 3, 6'-hexachloro-diphenylmethane (G 1 1) display synergistic bacteriostatic effect.
  • TCC 3,4,4'-trichlorocarbanilide
  • TBS 3,5,4'-tribromo-salicylanilide
  • G 1 1 2,2-dihydroxy-3, 5, 6, 3, 6'-hexachloro-diphenylmethane
  • the invention further includes synergistic bacteriostatic mixtures of the sal icylanilides of the invention with 3,4,4'-trichlorocarbanilide, 3 .5 ,4-tribromosalicylanilide or 2.2 -dihydroxy-3,5,6,3',5.6'- hexachIoro-diphenylmethane.
  • another aspect of the invention is a germicidal composition containing a synergistic bacteriostatic mixture of a salicylanilide of the invention and 3,4,4'-trichlorocarbanilide, 3,5,4-tribromosalicylanilide or 2, 2'-dihydroxy-3. 5, 6, 3', 5, 6-hexachloro-diphenylmethane.
  • a further aspect of the invention is a saponaceous composition containing a synergistic bacteriostatic mixture of a salicylanilide of the invention and 3,4,4-trichlorocarbani- Iide, 3,5,4'-tribromosalicylanilide or 2,2-dihydroxy-3.5,6,3. 5Z6-hexachloro-diphenylmethane.
  • the salicylanilides of the invention can be prepared by a variety of methods. For example, one method is the condensation of a haloaminodiphenylether (A) with a halogen-substituted salicylic acid (B), A and B being prepared by standard methods for the preparation of such compounds; another method is the direct halogenation of a phenoxy salicylanilide.
  • A haloaminodiphenylether
  • B halogen-substituted salicylic acid
  • a and B being prepared by standard methods for the preparation of such compounds
  • another method is the direct halogenation of a phenoxy salicylanilide.
  • the finger imprint rating of the compound was determined TBS G11 M.l.C. 0.2 0.5 0.6
  • EXAMPLE 4 3 ,5,3'-trichloro-6'-phenoxy-salicylanilide. Melting point 15 l152 C; M.l.C. 0.8.
  • EXAMPLE 5 5,3-dichloro-6'-phenoxy-salicylanilide. Melting point 163-164 C; M.l.C. 0.1.
  • EXAMPLE 7 3'-chloro-6-(p-chlorophenoxy)-salicylanilide. Melting point 169-171 C; M.l.C. 1.0.
  • EXAMPLE 8 3-chloro-6'-phenoxy-salicylanilide. Meltin gpoint 1S2l54 C; M.l.C. 0.24.
  • EXAMPLE 9 The M.l.C. of mixtures of the compounds of Examples l-8 with TCC, TBS and G 1 1 were obtained and compared with the MIC to be expected. The results are shown in Table I below:
  • the M.I.C. of the compound was 0.5
  • the compounds were prepared by a method similar to that described in Example 10.
  • EXAMPLE 18 The MIC of mixtures of the compounds of Examples 1 l-l with TCC, TBS and G1 I were compared with the MIC to be expected, as in Example 9. The results are shown in Table II below.
  • Example TCC TBS G1 I 1 l l2 H H The halogenated amino diphenyl ethers employed in Examples l and were synthesized by zinc/dilute acid reduction of the corresponding nitro compound using a five to six-fold excess of zinc. 'I'he nitro compound was obtained via an Ullmann synthesis using conditions similar to those described by R.V. Henley, J. Chem. Soc., 1222 (1930).
  • a salicylanilide having from 0 to 8 halogen atoms selected from the class consisting of chlorine and bromine on the salicylanilide residue and wherein one of the aromatic carbon atoms in the aniline ring bears a substituent selected from the class consisting of phenoxy and halogenated phenoxy groups having from I to 3 halogen atoms selected from the class consisting of chlorine and bromine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The specification discloses salicylanilides and halogenated salicylanilides wherein either or both the aniline or salicyl rings are substituted with a member of the class consisting of phenoxy and halophenoxy groups and the use of these compounds as effective germicides particularly in detergent compositions, such as soap bars.

Description

I United States Patent [151 3,674,850
Osborne 1 July 4, 1972 [54] SUBSTITUTED SALICYLANILIDES 58 Field of Search ..260/559 [72] Inventor: David Richard Duke Osborne, Bedford, [56] References Cited England [73] Assignee: Lever Brothers Company, New York, UNITED STATES PATENTS NY. 3,013,058 12/1961 Ritchter ..260/559 [22] Flled: 1969 Primary Examiner-Henry R. Jiles [21] Appl.No.: 887,427 Assistant Examiner-Harry l.Moat1 Attorney-Brumbaugh, Graves, Donohue & Raymond Related US. Application Data [63] Continuation of Ser. NO. 764,040, Sept. 25, 1968, [57] ABSTRACT Continuation of Ser. No. 51 1,989, Dec. 6, 1965. The specification discloses salicylanilides and halogenated salicylanilides wherein either or both the aniline or salicyl rings [30] Foreign Application Priority Data are substituted with a member of the class consisting of phenoxy and halophenoxy groups and the use of these com- Dec. 7, 1969 Great Britain ..49,805/64 pounds as effective germicides particularly in detergent positions, such as soap bars. [52] US. Cl. ..260/559 S, 424/324 [51] Int. Cl ..C07c 103/38 21 Claims, N0 Drawings SUBSTITUTED SALICYLANILIDES This application is a continuation of my United States application Ser. No. 764,040, filed Sept. 25, 1968, which in turn is a continuation of my United States application Ser. No. 511,989, filed Dec. 6, 1965.
The present invention relates to a new class of gerrnicides.
It is well known that halogenated salicylanilides have germicidal properties. The use of such compounds is described in Angew. Chem., 1955, 67, 145 (D. Jerchel and H. Oberheiden) and J. Pharm. Sci., 1961, 50, 831 (H. Lemaire, C.H. Schrarnm and A. Cahn).
It has now been discovered that the effectiveness of such compounds as gerrnicides can be increased by modifying their molecular structure by replacing at least one of the H atoms attached to C in either or both of the aromatic rings of the salicylanilide residue by a phenoxy or halogenated phenoxy group. It has also been found that the similar introduction of a phenoxy or halogenated phenoxy group into salicylanilide itself results in a useful germicide. As halogen, chlorine and bromine are particularly suitable.
Accordingly, the invention provides a salicylanilide wherein at least one of the H atoms attached to C in either or'both of the aromatic rings of the salicylanilide residue is replaced by a phenoxy or halogenated phenoxy group of from zero to the total number of the remaining H atoms attached to C in said aromatic rings in replaced by halogen.
The compounds where the phenoxy substituent is in th aniline ring of the salicylanilide are preferred.
Another aspect of the invention is a germicidal composition containing a salicylanilide of the invention.
The salicylanilides of the invention have been found to be effective in soap against both gram-positive (Staph. aureus) and gram-negative (E. coli) bacteria. Accordingly, another aspect of the invention is a saponaceous composition containing a salicylanilide of the invention.
It has also been discovered that mixtures of the salicylanilides of the invention with certain well known germicides for use in detergent compositions, namely, 3,4,4'-trichlorocarbanilide (TCC), 3,5,4'-tribromo-salicylanilide (TBS) and 2,2-dihydroxy-3, 5, 6, 3, 6'-hexachloro-diphenylmethane (G 1 1) display synergistic bacteriostatic effect. The invention further includes synergistic bacteriostatic mixtures of the sal icylanilides of the invention with 3,4,4'-trichlorocarbanilide, 3 .5 ,4-tribromosalicylanilide or 2.2 -dihydroxy-3,5,6,3',5.6'- hexachIoro-diphenylmethane. Accordingly, another aspect of the invention is a germicidal composition containing a synergistic bacteriostatic mixture of a salicylanilide of the invention and 3,4,4'-trichlorocarbanilide, 3,5,4-tribromosalicylanilide or 2, 2'-dihydroxy-3. 5, 6, 3', 5, 6-hexachloro-diphenylmethane. A further aspect of the invention is a saponaceous composition containing a synergistic bacteriostatic mixture of a salicylanilide of the invention and 3,4,4-trichlorocarbani- Iide, 3,5,4'-tribromosalicylanilide or 2,2-dihydroxy-3.5,6,3. 5Z6-hexachloro-diphenylmethane.
The salicylanilides of the invention can be prepared by a variety of methods. For example, one method is the condensation of a haloaminodiphenylether (A) with a halogen-substituted salicylic acid (B), A and B being prepared by standard methods for the preparation of such compounds; another method is the direct halogenation of a phenoxy salicylanilide.
EXAMPLE 1.
3,5,3'-trichloro-6'-(p-chlorophenoxy)-salicylanilide.
A slurry of 1.8 g. of 4,4'-dichloro-2-amino diphenyl ether and 1.4 g. 3,5-dichlorosalicylic acid in ml. of xylene was refluxed with 0.3 m1. of phosphorus trichloride for 3 hours and the reaction mixture filtered hot. The solution on cooling deposited 1.6 g. (51 Percent) of 3,5,3'-trichloro-6'-(pchlorophenoxy)-salicyanilide which was recrystallized from a benzene-petroleum ether mixture to give crystals of m.p. 195-196 C.
The finger imprint rating of the compound was determined TBS G11 M.l.C. 0.2 0.5 0.6
In each of the following Examples, the compounds were prepared by a method similar to that described in Example 1.
EXAMPLE 2.
3,5,3'-trichloro-6'-(o-chlorophenoxy)-salicylanilide. Melting point 193-195 C; M.l.C. 1.0.
EXAMPLE 3 5 ,3 -(o-chlorophenoxy )-salicylanilide. Melting point l73175C; M.l.C. 0.3.
EXAMPLE 4 3 ,5,3'-trichloro-6'-phenoxy-salicylanilide. Melting point 15 l152 C; M.l.C. 0.8.
EXAMPLE 5 5,3-dichloro-6'-phenoxy-salicylanilide. Melting point 163-164 C; M.l.C. 0.1.
EXAMPLE 6 3-chloro-6-(o-chlorophenoxy)-salicylanilide. Melting point 142-l44 C; M.l.C. 3.0.
EXAMPLE 7 3'-chloro-6-(p-chlorophenoxy)-salicylanilide. Melting point 169-171 C; M.l.C. 1.0.
EXAMPLE 8 3-chloro-6'-phenoxy-salicylanilide. Meltin gpoint 1S2l54 C; M.l.C. 0.24.
EXAMPLE 9 The M.l.C. of mixtures of the compounds of Examples l-8 with TCC, TBS and G 1 1 were obtained and compared with the MIC to be expected. The results are shown in Table I below:
indicates no synergism indicates synergism indicates marked synergism Example TCC TBS G 1 1 1 2 +1- 3 4 5 EXAMPLE l0 3,5,3-Trichloro-6'-(2,4,5-trichlorophenoxy)-salicylanilide.
A mixture of 11.7g (0.036 moles) of 2,4,5,4'-tetrachloro-2 '-aminodiphenyl ether, 8.3g (0.04 moles) of 3,5-dichloro salicylic acid and 1.8 ml. of phosphorus trichloride in 125 ml. of chlorobenzene was refluxed for 3 hours, filtered hot and allowed to crystallize. 12.9g (70.1 percent) of a solid (melting point 1947 C) was obtained which, after 4 recrystallizations from chlorobenzene had a melting point of 201-4C, and was shown to be pure by thin layer chromatography on silica,
by the method described in J. Phannacol. Sci., 1961, 50, 827. eluted with petroleum ether: acetone: acetic acid, (:5:2).
The M.I.C. of the compound was 0.5 In each of the following Examples, the compounds were prepared by a method similar to that described in Example 10.
EXAMPLE ll 5,3'-dichloro-6'-(p-chlorophenoxy)-salicylanilide. MIC 0.1
EXAMPLE l2 3,5,3-tribromo-6'-(p-bromophenoxy)-salicylanilide. MIC 0.6
3,5-dichloro-6-(p-chlorophenoxy)-salicylanilide. MIC 0.2 m.p. l58-9 C.
EXAMPLE l7 3,5-dichloro-6-(o-chlorophenoxy)-salicylanilide. MIC 0.9 m.p. l55-6C.
EXAMPLE 18 The MIC of mixtures of the compounds of Examples 1 l-l with TCC, TBS and G1 I were compared with the MIC to be expected, as in Example 9. The results are shown in Table II below.
Example TCC TBS G1 I 1 l l2 H H The halogenated amino diphenyl ethers employed in Examples l and were synthesized by zinc/dilute acid reduction of the corresponding nitro compound using a five to six-fold excess of zinc. 'I'he nitro compound was obtained via an Ullmann synthesis using conditions similar to those described by R.V. Henley, J. Chem. Soc., 1222 (1930).
What is claimed is:
1. A salicylanilide having from 0 to 8 halogen atoms selected from the class consisting of chlorine and bromine on the salicylanilide residue and wherein one of the aromatic carbon atoms in the aniline ring bears a substituent selected from the class consisting of phenoxy and halogenated phenoxy groups having from I to 3 halogen atoms selected from the class consisting of chlorine and bromine.
2. A salicylanilide having from O to 8 halogen atoms selected from the class consisting of chlorine and bromine on the salicylanilide residue and wherein the carbon atom in the 6' position in the aniline ring bears a substituent selected from the class consisting of phenoxy and halogenated phenoxy groups having from 1 to 3 halogen atoms selected from the class consisting of chlorine and bromine.
3. A salicylanilide according to claim 1 in which the halogenated phenoxy substituent is a p-chloro-phenoxy group.
4. A salicylanilide according to claim 1 in which the halogen substituent or substituents in the aromatic ring or rings is chlorine.
5. 3,5,3-trichloro-6'-(p-chlorophenoxy)-salicylanilide.
6. 3,5,3-trichloro-6'-(o-chlorophenoxy)-salicylanilide.
7. 5,3'-dichloro-6-(o-chlorophenoxy)-salicylanilide.
8. 3,5,3'-trichloro-6'-phenoxy-salicylanilide.
9. 5,3-dichIoro-6'-phenoxy-salicylanilide.
l0. 3-chloro-6-(o-chlorophenoxy)-salicylanilide.
I l. 3'-chloro-6'-(pl-chlorophenoxy):salicylanilide.
12.3'-chloro-6- enoxy-sallcylamlide.
l3. 3,5,3'-trichloro-6'-(2,4,5-trichlorophenoxy)-salicylanilide.
l4. 5,3-dichloro-6-(p-chlorophenoxy)-salicylanilide.
15. 3,5,3-tribromo-6'-(p-bromophenoxy)-salicylanilide.
16. 6-(p-chlorophenoxy)salicylanilide.
I7. 5'-chloro-6-phenoxy-salicylanilide.
I8. 3,5-dichlor0-6'-phenoxy-salicylanilide.
19. 3,5dichloro-6-(p-chlorophenoxy)-salicylanilide.
20. 3.5-dichloro-6-(ochlorophenoxy)-salicylanilide.
21. A salicylanilide having from zero to eight halogen atoms on the salicylanilide residue and wherein one of the aromatic carbon atoms in the aniline ring bears a substituent selected from the class consisting of phenoxy and halogenated phenoxy groups having from one to three halogen atoms.
l i i

Claims (20)

  1. 2. A salicylanilide having from 0 to 8 halogen atoms selected from the class consisting of chlorine and bromine on the salicylanilide residue and wherein the carbon atom in the 6'' position in the aniline ring bears a substituent selected from the class consisting of phenoxy and halogenated phenoxy groups having from 1 to 3 halogen atoms selected from the class consisting of chlorine and bromine.
  2. 3. A salicylanilide according to claim 1 in which the halogenated phenoxy substituent is a p-chloro-phenoxy group.
  3. 4. A salicylanilide according to claim 1 in which the halogen substituent or substituents in the aromatic ring or rings is chlorine.
  4. 5. 3,5,3''-trichloro-6-(p-chlorophenoxy)-salicylanilide.
  5. 6. 3,5,3''-trichloro-6''-(o-chlorophenoxy)-salicylanilide.
  6. 7. 5,3''-dichloro-6''-(o-chlorophenoxy)-salicylanilide.
  7. 8. 3,5,3-trichloro-6''-phenoxy-salicylanilide.
  8. 9. 5,3''-dichloro-6''-phenoxy-salicylanilide.
  9. 10. 3''-chloro-6''-(o-chlorophenoxy)-salicylanilide.
  10. 11. 3''-chloro-6''-(p-chlorophenoxy)-salicylanilide.
  11. 12. 3''-chloro-6''-phenoxy-salicylanilide.
  12. 13. 3,5,3''-trichloro-6''-(2,4,5-trichlorophenoxy)-salicylanilide.
  13. 14. 5,3''-dichloro-6''-(p-chlorophenoxy)-salicylanilide.
  14. 15. 3,5,3''-tribromo-6-(p-bromophenoxy)-salicylanilide.
  15. 16. 6''-(p-chlorophenoxy)-salicylanilide.
  16. 17. 5''-chloro-6''-phenoxy-salicylanilide.
  17. 18. 3,5-dichloro-6-phenoxy-salicylanilide.
  18. 19. 3,5-dichloro-6''-(p-chlorophenoxy)-salicylanilide.
  19. 20. 3,5-dichloro-6''-(o-chlorophenoxy)-salicylanilide.
  20. 21. A salicylanilide having from zero to eight halogen atoms on the salicylanilide residue and wherein one of the aromatic carbon atoms in the aniline ring bears a substituent selected from the class consisting of phenoxy and halogenated phenoxy groups having from one to three halogen atoms.
US887427A 1969-12-07 1969-12-22 Substituted salicylanilides Expired - Lifetime US3674850A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4980569 1969-12-07

Publications (1)

Publication Number Publication Date
US3674850A true US3674850A (en) 1972-07-04

Family

ID=10453600

Family Applications (1)

Application Number Title Priority Date Filing Date
US887427A Expired - Lifetime US3674850A (en) 1969-12-07 1969-12-22 Substituted salicylanilides

Country Status (1)

Country Link
US (1) US3674850A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914418A (en) * 1971-09-02 1975-10-21 Merck & Co Inc Methods of controlling liver fluke infections
EP1503986A2 (en) * 2001-12-21 2005-02-09 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20050187300A1 (en) * 2002-07-15 2005-08-25 Myriad Genetics, Incorporated Compounds, compositions, and methods employing same
US20100121107A1 (en) * 2008-07-21 2010-05-13 Chi-Huey Wong Crystal structure of bifunctional transglycosylase pbp1b from e. coli and inhibitors thereof
EP3338783A1 (en) * 2014-09-12 2018-06-27 AntibioTx A/S Antibacterial use of halogenated salicylanilides
WO2019192968A1 (en) * 2018-04-03 2019-10-10 UNION therapeutics A/S Treatment of infections caused by neisseria gonococcus using a halogenated salicylanilide
US10463680B2 (en) 2015-05-29 2019-11-05 UNION therapeutics A/S Halogenated salicylanilides for treating clostridium infections
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US12036312B2 (en) 2016-03-16 2024-07-16 UNION therapeutics A/S Non-aqueous topical compositions comprising a halogenated salicylanilide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3013058A (en) * 1958-10-15 1961-12-12 Velsicol Chemical Corp 2-methoxy-3, 6-dichlorophenylacetates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3013058A (en) * 1958-10-15 1961-12-12 Velsicol Chemical Corp 2-methoxy-3, 6-dichlorophenylacetates

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914418A (en) * 1971-09-02 1975-10-21 Merck & Co Inc Methods of controlling liver fluke infections
EP1503986A2 (en) * 2001-12-21 2005-02-09 Cytokinetics, Inc. Compositions and methods for treating heart failure
US6908923B2 (en) 2001-12-21 2005-06-21 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20050148638A1 (en) * 2001-12-21 2005-07-07 Cytokinetics, Inc. Compositions and methods for treating heart failure
EP1503986A4 (en) * 2001-12-21 2005-11-30 Cytokinetics Inc Compositions and methods for treating heart failure
US7053094B2 (en) 2001-12-21 2006-05-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20060173024A1 (en) * 2001-12-21 2006-08-03 Cytokinetics, Inc. Compositions and methods for treating heart failure
US7605164B2 (en) 2001-12-21 2009-10-20 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20050187300A1 (en) * 2002-07-15 2005-08-25 Myriad Genetics, Incorporated Compounds, compositions, and methods employing same
US7547804B2 (en) 2002-07-15 2009-06-16 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
US9890111B2 (en) 2008-07-21 2018-02-13 Academia Sinica Crystal structure of bifunctional transglycosylase PBP1b from E. coli and inhibitors thereof
US20100121107A1 (en) * 2008-07-21 2010-05-13 Chi-Huey Wong Crystal structure of bifunctional transglycosylase pbp1b from e. coli and inhibitors thereof
US20150232417A1 (en) * 2008-07-21 2015-08-20 Academia Sinica Crystal structure of bifunctional transglycosylase pbp1b from e. coli and inhibitors thereof
US11285164B2 (en) 2014-09-12 2022-03-29 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
EP3338783A1 (en) * 2014-09-12 2018-06-27 AntibioTx A/S Antibacterial use of halogenated salicylanilides
US11331327B2 (en) 2014-09-12 2022-05-17 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
US11324761B2 (en) 2014-09-12 2022-05-10 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
US10758553B2 (en) 2014-09-12 2020-09-01 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
EP3967312A1 (en) * 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
US10857164B2 (en) 2015-05-29 2020-12-08 UNION therapeutics A/S Halogenated salicylanilides for treating Clostridium infections
US10463680B2 (en) 2015-05-29 2019-11-05 UNION therapeutics A/S Halogenated salicylanilides for treating clostridium infections
US11529361B2 (en) 2015-05-29 2022-12-20 UNION therapeutics A/S Halogenated salicylanilides for treating Clostridium infections
US12036312B2 (en) 2016-03-16 2024-07-16 UNION therapeutics A/S Non-aqueous topical compositions comprising a halogenated salicylanilide
WO2019192968A1 (en) * 2018-04-03 2019-10-10 UNION therapeutics A/S Treatment of infections caused by neisseria gonococcus using a halogenated salicylanilide
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide

Similar Documents

Publication Publication Date Title
US3674850A (en) Substituted salicylanilides
HK57197A (en) Naphthalene derivatives procedure for their preparation and pharmaceutical compositions containing them
FI940105A0 (en) Processes for the preparation of sertraline intermediates
US3564607A (en) Halogenated aryloxyacetyl cyanamides
ATE54153T1 (en) ANDROSTANE-17BETA CARBONATE, A PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION, COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY CONDITIONS.
FI940106A0 (en) Process for the preparation of sertraline
US3050440A (en) New fungicidal compositions of matter
US2562208A (en) Fungistatic composition
GB1585963A (en) Aryl sulphur compounds
US2162211A (en) Organic mercury compound
US2865861A (en) Halogenated-3-phenylsalicylanilides
Angier et al. Pteroic Acid Analogs Containing Arsenic
US3706799A (en) Naphthyloxysalicylanilides
GB1577725A (en) Azetidinone derivatives
US3686331A (en) Anti-microbial phenyl 3-halopropargyl ethers
US2730551A (en) Halogenated tris-phenols
US2739941A (en) Germicidal soap composition
USRE24868E (en) Halophenyl j
US2702302A (en) Amine salts of bis (2-hydroxy-3-bromo-5-chlorophenyl) sulfide
US2671787A (en) Tetrachlorobenzoguanamines
US3625990A (en) O-acylbenzohydorxamates
US3649718A (en) Halogenated phenyl alkylene phosphinates
US3787507A (en) Halogenated benzylphenols having bacteriostatic activity
GB1563850A (en) Phenoxy-phenoxy-alkane carboxylic acid derivatives process for their preparation and compositions containing them
US2085063A (en) Organic mercury compounds